Please fax all pages of completed form to your team at 888.302.1028.
To reach your team, call toll-free 844.516.3319.
You can now monitor shipments and chat online if you have questions. Go to MyAccredoPatients.com to log in or get started.

Accredo® Specialty Pharmacy Prescription & Enrollment Form

Kisunla™ (donanemab-azbt)

EVERNORTH HEALTH SERVICES

Four simple steps to submit your referral.

1 Patient Information

Please provide copies of front and back of all medical and prescription insurance cards.

☐ New patient ☐ Current patient

Patient's first name _____ Last name _____ Middle initial _____

Preferred patient first name _____ Preferred patient last name _____

Sex at birth: ☐ Male ☐ Female Gender identity _____ Pronouns _____ Last 4 digits of SSN _____

Date of birth _____ Street address _____ Apt # _____

City _____ State _____ Zip _____

Home phone _____ Cell phone _____ Email address _____

Parent/guardian (if applicable) _____

Home phone _____ Cell phone _____ Email address _____

Alternate caregiver/contact _____

Home phone _____ Cell phone _____ Email address _____

☐ OK to leave message with alternate caregiver/contact

Patient's primary language: ☐ English ☐ Other If other, please specify _____

Provider will read the following statement to patient: By providing the phone number(s) and email address above, you consent to receiving automated/artificial voice calls, emails and/or text messages from Accredo about your prescription(s), account, and health care. Standard data rates apply. Message frequency varies.

2 Prescriber Information

All fields must be completed to expedite prescription fulfillment.

Date _____ Time _____ Date medication needed _____

Office/clinic/institution name _____

Prescriber info: Prescriber's first name _____ Last name _____

Prescriber's title _____ If NP or PA, under direction of Dr. _____

Office phone _____ Fax _____ NPI # _____ License # _____

Office contact and title _____ Office contact email _____

Office street address _____ Suite # _____

City _____ State _____ Zip _____

Infusion location: ☐ Patient's home ☐ Prescriber's office ☐ Infusion site If infusion site, complete information below dotted line:

Infusion info: Infusion site name _____ Clinic/hospital affiliation _____

Site street address _____ Suite # _____

City _____ State _____ Zip _____

Infusion site contact _____ Phone _____ Fax _____ Email _____

3 Clinical Information

Primary ICD-10 code (REQUIRED): _____ Has the patient been treated previously for this condition? ☐ Yes ☐ No

Is the patient currently on therapy? ☐ Yes ☐ No Please list all therapies tried/failed: _____

Patient wt _____ Date wt obtained _____

☐ NKDA ☐ Known drug allergies _____

Concurrent meds _____

Patient's first name _____ Last name _____ Middle initial _____ Date of birth _____

Prescriber's first name _____ Last name _____ Phone _____

Diagnosis:

- ☐ G30.0 Alzheimer's disease with early onset
- ☐ G30.1 Alzheimer's disease with late onset
- ☐ G30.8 Other Alzheimer's disease
- ☐ G30.9 Alzheimer's disease, unspecified
- ☐ G31.84 Mild cognitive impairment, so stated
- ☐ Other: _____

Date of last MRI negative for ARIA: _____

Evidence of amyloid positivity confirmed via:

- ☐ PET scan
- ☐ CSF sample
- ☐ Plasma sample
- ☐ Date: _____

4 Prescribing Information

Medication	Strength/Formulation	Directions	Quantity/Refills
☐ Kisunla™ (donanemab-azbt) single-dose vial **Medicare beneficiaries (required by CMS):** NCT registry number: _____ CED submission number: _____ CED submission date: _____	350mg/20mL (17.5mg/mL)	☐ **Titration:** Infuse intravenously over approximately 30 minutes once every 4 weeks as follows: Infusion 1: 350mg Infusion 2: 700mg Infusion 3: 1050mg If patient needs partial titration dose, indicate what is needed: ☐ Infusion 2 and Infusion 3 ☐ Infusion 3 only	28-day supply Refills: ☐ 11 ☐ Other _____
		☐ **Maintenance Dose:** Infuse 1400mg intravenously over approximately 30 minutes at infusion 4 and then once every 4 weeks thereafter	
		Attention Providers: • Dilute prior to administration in 0.9% normal saline to package labeling recommended final concentration range of 4mg/mL to 10mg/mL. • Observe patients post-infusion for a minimum of 30 minutes for infusion reactions and hypersensitivity. • MRIs must be obtained before starting and prior to infusions 2, 3, 4 and 7 to monitor for ARIA, and as needed if symptoms consistent with ARIA occur. • Due to increased risk of ARIA-E, alternate titration regimens are not recommended in current package labeling.	
☐ Other			

Dispense needles, syringes, ancillary supplies and home medical equipment necessary to administer medication.

If shipped to physician's office, physician accepts on behalf of patient for administration in office.

Prescriber's signature required (sign below) (Physician attests this is his/her legal signature. NO STAMPS)

SIGN HERE

_____ **Date** _____ **Dispense as written** _____ **Date** _____ **Substitution allowed**

The prescriber is to comply with his/her state-specific prescription requirements such as e-prescribing, state-specific prescription form, fax language, etc. Non-compliance with state-specific requirements could result in outreach to the prescriber.

EVERNORTH HEALTH SERVICES

The document(s) accompanying this transmission may contain confidential health information that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party unless required to do so by law or regulation. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender immediately and arrange for the return or destruction of these documents. All rights in the product names, trade names or logos of all third-party products that appear in this form, whether or not appearing with the trademark symbol, belong exclusively to their respective owners. © 2026 Evernorth Health Services. All rights reserved. NEU-00006-012226 CRP1357514